Development and Validation of a Remote Monitoring Tool for Assessment of Mild, Moderate, and Severe Infections in Inflammatory Bowel Disease.
IBD
Remote monitoring tool
development
infections
real-world data
validation
Journal
Journal of Crohn's & colitis
ISSN: 1876-4479
Titre abrégé: J Crohns Colitis
Pays: England
ID NLM: 101318676
Informations de publication
Date de publication:
05 Jul 2023
05 Jul 2023
Historique:
medline:
6
7
2023
pubmed:
17
2
2023
entrez:
16
2
2023
Statut:
ppublish
Résumé
Immunomodulators and biologics are cornerstones in the management of inflammatory bowel disease [IBD], but are associated with increased risk of infections. Post-marketing surveillance registries are pivotal to assess this risk, yet mainly focus on severe infections. Data on the prevalence of mild and moderate infections are scarce. We developed and validated a remote monitoring tool for real-world assessment of infections in IBD patients. A 7-item Patient-Reported Infections Questionnaire [PRIQ] covering 15 infection categories was developed with a 3-month recall period. Infection severity was defined as mild [self-limiting or topical treatment], moderate [oral antibiotics, antivirals, or antifungals], or severe [hospitalisation or intravenous treatment]. Comprehensiveness and comprehensibility were ascertained through cognitive interviewing of 36 IBD outpatients. After implementation in the telemedicine platform myIBDcoach, a prospective, multicentre cohort study was performed between June 2020 and June 2021 in 584 patients, to assess diagnostic accuracy. Events were cross-checked with general practitioner and pharmacy data [gold standard]. Agreement was evaluated using linear-weighted kappa with cluster-bootstrapping to account for within-patient level correlation. Patient understanding was good and interviews did not result in reduction of PRIQ items. During validation, 584 IBD patients {57.8% female, mean age 48.6 (standard deviaton [SD]: 14.8), disease duration 12.6 years [SD: 10.9]} completed 1386 periodic assessments, reporting 1626 events. Linear-weighted kappa for agreement between PRIQ and gold standard was 0.92 (95% confidence interval [CI] 0.89-0.94). Sensitivity and specificity for infection [yes/no] were 93.9% [95% CI 91.8-96.0] and 98.5% [95% CI 97.5-99.4], respectively. The PRIQ is a valid and accurate remote monitoring tool to assess infections in IBD patients, providing means to personalise medicine based on adequate benefit-risk assessments.
Sections du résumé
BACKGROUND
BACKGROUND
Immunomodulators and biologics are cornerstones in the management of inflammatory bowel disease [IBD], but are associated with increased risk of infections. Post-marketing surveillance registries are pivotal to assess this risk, yet mainly focus on severe infections. Data on the prevalence of mild and moderate infections are scarce. We developed and validated a remote monitoring tool for real-world assessment of infections in IBD patients.
METHODS
METHODS
A 7-item Patient-Reported Infections Questionnaire [PRIQ] covering 15 infection categories was developed with a 3-month recall period. Infection severity was defined as mild [self-limiting or topical treatment], moderate [oral antibiotics, antivirals, or antifungals], or severe [hospitalisation or intravenous treatment]. Comprehensiveness and comprehensibility were ascertained through cognitive interviewing of 36 IBD outpatients. After implementation in the telemedicine platform myIBDcoach, a prospective, multicentre cohort study was performed between June 2020 and June 2021 in 584 patients, to assess diagnostic accuracy. Events were cross-checked with general practitioner and pharmacy data [gold standard]. Agreement was evaluated using linear-weighted kappa with cluster-bootstrapping to account for within-patient level correlation.
RESULTS
RESULTS
Patient understanding was good and interviews did not result in reduction of PRIQ items. During validation, 584 IBD patients {57.8% female, mean age 48.6 (standard deviaton [SD]: 14.8), disease duration 12.6 years [SD: 10.9]} completed 1386 periodic assessments, reporting 1626 events. Linear-weighted kappa for agreement between PRIQ and gold standard was 0.92 (95% confidence interval [CI] 0.89-0.94). Sensitivity and specificity for infection [yes/no] were 93.9% [95% CI 91.8-96.0] and 98.5% [95% CI 97.5-99.4], respectively.
CONCLUSIONS
CONCLUSIONS
The PRIQ is a valid and accurate remote monitoring tool to assess infections in IBD patients, providing means to personalise medicine based on adequate benefit-risk assessments.
Identifiants
pubmed: 36795060
pii: 7043219
doi: 10.1093/ecco-jcc/jjad023
pmc: PMC10320484
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1079-1088Subventions
Organisme : Takeda
ID : IISR-2019-102915
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.
Références
Clin Gastroenterol Hepatol. 2016 Oct;14(10):1385-1397.e10
pubmed: 27189910
Gut. 2008 Apr;57(4):549-58
pubmed: 18178610
Int J Epidemiol. 2017 Apr 1;46(2):e7
pubmed: 26045509
Gastroenterology. 2008 Apr;134(4):929-36
pubmed: 18294633
J Crohns Colitis. 2021 May 4;15(5):869-870
pubmed: 33179021
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
BMJ Open Gastroenterol. 2021 Feb;8(1):
pubmed: 33597152
Inflamm Bowel Dis. 2007 Oct;13(10):1244-9
pubmed: 17538983
Lancet. 2017 Sep 2;390(10098):959-968
pubmed: 28716313
J Crohns Colitis. 2021 Apr 6;15(4):540-550
pubmed: 33035299
Dig Liver Dis. 2011 Jul;43(7):535-41
pubmed: 21315666
Middle East J Dig Dis. 2016 Apr;8(2):116-21
pubmed: 27252818
BMC Musculoskelet Disord. 2016 Aug 04;17:322
pubmed: 27491386
Am J Gastroenterol. 2012 Sep;107(9):1409-22
pubmed: 22890223
J Clin Epidemiol. 2010 Dec;63(12):1358-62
pubmed: 20430581
Aliment Pharmacol Ther. 2020 Oct;52(8):1353-1365
pubmed: 32876349
Biochem Med (Zagreb). 2012;22(3):276-82
pubmed: 23092060
Clin Gastroenterol Hepatol. 2022 Mar;20(3):578-590.e4
pubmed: 33618023
J Crohns Colitis. 2017 Jun 01;11(6):680-689
pubmed: 28025307
Gastroenterol Hepatol. 2022 Aug-Sep;45(7):524-534
pubmed: 34428475
Drug Saf. 2020 Sep;43(9):917-925
pubmed: 32451974
Stat Methods Med Res. 2019 Oct-Nov;28(10-11):3012-3026
pubmed: 30132375
Inflamm Bowel Dis. 2004 May;10(3):261-9
pubmed: 15290922
J Crohns Colitis. 2014 May;8(5):349-56
pubmed: 24183653
J Crohns Colitis. 2021 Apr 6;15(4):529-539
pubmed: 33079178
Crohns Colitis 360. 2021 Jun 09;3(3):otab031
pubmed: 36776667
BMC Gastroenterol. 2017 Apr 14;17(1):52
pubmed: 28407755
Dig Dis Sci. 2021 Sep;66(9):2935-2941
pubmed: 32995995
Aliment Pharmacol Ther. 2009 May 15;29(10):1106-13
pubmed: 19222411
Value Health. 2005 Mar-Apr;8(2):94-104
pubmed: 15804318
Scand J Gastroenterol. 2021 Feb;56(2):155-161
pubmed: 33300822
Gastroenterology. 2018 Aug;155(2):337-346.e10
pubmed: 29655835
Adv Ther. 2020 Jan;37(1):364-380
pubmed: 31748904
PLoS One. 2021 Oct 5;16(10):e0258271
pubmed: 34610041
J Health Econ. 2014 May;35:34-46
pubmed: 24595066
Gastroenterol Hepatol. 2021 Dec;44(10):711-718
pubmed: 33872624
Clin Gastroenterol Hepatol. 2020 Jan;18(1):69-81.e3
pubmed: 30876964
J Crohns Colitis. 2013 Mar;7(2):107-12
pubmed: 22440891
Curr Med Res Opin. 2009 Apr;25(4):929-42
pubmed: 19257798
Lancet. 2015 Jul 18;386(9990):258-65
pubmed: 25975452
Caspian J Intern Med. 2015 Winter;6(1):20-4
pubmed: 26221492
J Crohns Colitis. 2021 Jun 22;15(6):879-913
pubmed: 33730753
Health Qual Life Outcomes. 2006 Oct 11;4:79
pubmed: 17034633
Clin Pharmacol Ther. 2017 Oct;102(4):633-641
pubmed: 28699217
Clin Gastroenterol Hepatol. 2020 Aug;18(9):2134-2135
pubmed: 32360811
United European Gastroenterol J. 2021 Mar;9(2):159-176
pubmed: 33210980
Intest Res. 2018 Oct;16(4):571-578
pubmed: 30301333
Ups J Med Sci. 2022 Jan 10;127:
pubmed: 35140875